{
  "$schema": "folio-library-entry/v1",
  "id": "10665-255866",
  "blocks": [
    {
      "id": "library/10665-255866/blocks/figure-img-p001-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-1.webp",
      "narrative": "draft",
      "content": "Cover photograph of a line of smiling women standing on grass outside a brick building with a solar panel on its roof, most of them holding babies or young children.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 4,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "PREVENTING HIV \nDURING PREGNANCY \nAND BREASTFEEDING IN \nTHE CONTEXT OF PREP\nJULY 2017\nTECHNICAL BRIEF\nWHO TECHNICAL BRIEF: Preventing HIV during pregnancy and breastfeeding in the context of PrEP\nWHO/HIV/2017.09 \n© World Health Organization 2017\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC \nBY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). \nUnder the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work \nis appropriately cited",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Front matter of the 2017 WHO technical brief on preventing HIV during pregnancy and breastfeeding in the context of PrEP, with title page, copyright and licence terms, acknowledgements and table of contents.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/sec-000-introduction.md",
      "narrative": null,
      "content": "In many countries with high-prevalence generalized HIV epidemics, women continue to acquire HIV during pregnancy and \nbreastfeeding. Women who become infected during this time also risk transmitting HIV to their infants. Incident HIV \ninfection during pregnancy and breastfeeding contributes to a significant proportion of infants with HIV in very high \nincidence settings, and is of public health relevance for antenatal services that seek to test and treat all women with HIV \nas part of programmes for prevention of mother-to-child transmission (PMTCT). \nSeveral strategies for preventing HIV infe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the technical brief by explaining that women in high-prevalence settings still acquire HIV during pregnancy and breastfeeding, raising the risk of transmission to infants. It notes established prevention measures and proposes oral PrEP as a complement, then lists the brief's aims.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "What is PrEP?",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/sec-001-what-is-prep.md",
      "narrative": null,
      "content": "PrEP is the use of daily oral tenofovir disoproxil fumarate (TDF) or co-formulated TDF/emtricitabine (TDF/FTC) to prevent \nHIV acquisition. PrEP has been shown to be effective in a wide range of HIV-negative populations.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines PrEP as daily oral TDF or TDF/FTC taken to prevent HIV acquisition by HIV-negative people.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "WHO recommendation on PrEP",
      "pageStart": 4,
      "pageEnd": 5,
      "target": "../sections/sec-002-who-recommendation-on-prep.md",
      "narrative": null,
      "content": "In 2015, the World Health Organization (WHO) recommended that oral PrEP containing TDF be offered as an additional \nprevention choice for people at substantial risk1 of HIV infection, as part of combination HIV prevention approaches (1). \nThis recommendation was based on a systematic review and meta-analysis (2) of high-quality evidence on PrEP’s \neffectiveness from clinical trial research. WHO included this recommendation in its 2016 update of the consolidated \nguidelines on the use of ARV drugs for treating and preventing HIV infection (3). \nThe 2016 WHO consolidated guidelines on the use of",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Outlines WHO's 2015 recommendation that oral TDF-containing PrEP be offered to people at substantial HIV risk and how the 2016 consolidated guidelines addressed its use in pregnancy and breastfeeding. It notes that the benefits of preventing maternal HIV and mother-to-child transmission were judged to outweigh potential risks of fetal and infant drug exposure.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/figure-vfig-p005",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../figures/vfig-p005.webp",
      "narrative": "draft",
      "content": "Page render with the 2015 WHO recommendation on PrEP (oral PrEP containing TDF should be offered as an additional prevention choice for people at substantial risk of HIV infection; high quality evidence, strong recommendation), a text section on why to offer PrEP to pregnant and breastfeeding women, and Figure 1, 'Women may be at increased risk of acquiring HIV during pregnancy, breastfeeding and the postpartum period'. The diagram links 'Biological Suseptibility' [sic] to elevated hormonal levels, untreated STIs and vaginal microbiome changes associated with cervical or genital inflammation, and nutritional deficiency and lowered immunity; 'Behavioural exposure' links to behaviour changes in women and male partners during the pregnancy/postpartum period. The figure is cut off at the bottom.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Why offer PrEP to pregnant and breastfeeding women?",
      "pageStart": 5,
      "pageEnd": 6,
      "target": "../sections/sec-003-why-offer-prep-to-pregnant-and-breastfeeding-wom.md",
      "narrative": null,
      "content": "Pregnant and breastfeeding women living in settings where HIV incidence is greater than three per 100 person–years, \nparticularly in sub-Saharan Africa, often remain at substantial and increased risk of HIV acquisition during pregnancy and \nbreastfeeding. Biological factors increase susceptibility, and social and behavioural factors may increase exposure to HIV \ninfection (Figure 1). Pregnant and breastfeeding women who acquire HIV at this time have a greater risk of transmitting \nHIV to their infant than women who became infected with HIV before pregnancy. \nFigure 1. Women may be at increased",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why pregnant and breastfeeding women in high-incidence settings face increased HIV risk, with a figure listing biological and behavioural factors. It also summarises WHO recommendations on antenatal HIV testing, retesting and partner testing as part of prevention.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PrEP safety during pregnancy and breastfeeding",
      "pageStart": 6,
      "pageEnd": 8,
      "target": "../sections/sec-004-prep-safety-during-pregnancy-and-breastfeeding.md",
      "narrative": null,
      "content": "The 2016 WHO guidelines state that there is no safety-related rationale for disallowing or discontinuing PrEP use during \npregnancy and breastfeeding for HIV-negative women who are receiving PrEP and remain at risk of HIV acquisition (1). The \nguidelines conclude that in such situations the benefits of preventing HIV acquisition in the mother, and the accompanying \nreduced risk of mother-to-child HIV transmission outweigh any potential risks of PrEP, including any risks of fetal and \ninfant exposure to TDF and FTC in PrEP regimens. The results from a WHO systematic review conducted in late 201",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews evidence on the safety of PrEP during pregnancy and breastfeeding, drawing on a 2016 WHO systematic review of TDF use in HIV-positive and HIV-negative women. It reports that few adverse pregnancy, birth or infant outcomes were linked to TDF, and discusses data on drug levels in breast milk and infant bone and renal effects. It concludes that PrEP can be used in pregnancy and breastfeeding and as part of safer conception.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Providing PrEP to women who would most benefit",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../sections/sec-005-providing-prep-to-women-who-would-most-benefit.md",
      "narrative": null,
      "content": "Although there is limited experience with the use of PrEP in antenatal and postnatal care services, it is an important new \nHIV prevention method to consider, particularly for high-burden settings where women remain at significant HIV risk. \nThere are three scenarios for which PrEP may be considered among HIV-negative pregnant and breastfeeding women:\n1.\t a woman taking PrEP who subsequently becomes pregnant and remains at substantial risk of HIV infection;\n2.\t a pregnant or breastfeeding HIV-negative woman living in a setting with high HIV incidence who is at substantial risk \nof HIV acquisit",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes three situations in which HIV-negative pregnant or breastfeeding women may be offered PrEP, together with testing, adherence counselling, monitoring and other prevention options.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PrEP as part of PMTCT in settings of high HIV incidence",
      "pageStart": 8,
      "pageEnd": 10,
      "target": "../sections/sec-006-prep-as-part-of-pmtct-in-settings-of-high-hiv-in.md",
      "narrative": null,
      "content": "For high burden settings and for populations with high HIV incidence in low burden settings, all HIV-negative women \nshould be offered prevention interventions at antenatal and postnatal visits (Box 1). In addition, PrEP could be offered as \npart of an enhanced comprehensive HIV prevention approach in selected sites where women experience ongoing high HIV \nincidence. Note that the other elements described in Box 1 should be considered for women in other antenatal and \npostnatal settings where PMTCT programmes are established but incidence does not warrant prioritization of PrEP. \n1\tThis could",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how PrEP can be added to comprehensive HIV prevention in antenatal and postnatal care where HIV incidence is high, setting out eight elements of such a package in a box. The elements include repeat testing, partner testing and referral, condoms, STI screening and risk counselling. It also discusses risk assessment tools while cautioning that they should not be used to deny PrEP to women who request it.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/figure-vfig-p009",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../figures/vfig-p009.webp",
      "narrative": "draft",
      "content": "Flowchart of a suggested prioritization framework for offering PrEP to pregnant and breastfeeding women (Figure 2). From antenatal registration with provider-initiated HIV testing and counselling, HIV-positive women receive PMTCT, treatment, support and partner notification; HIV-negative women receive post-test counselling, partner testing and a risk assessment using a tool. A partner who is HIV-negative leads to reassessing the woman's risk and referring the partner for VMMC; a partner not tested or HIV-positive, or a positive risk assessment, identifies a woman at substantial risk, who is offered comprehensive prevention (STI screening and treatment, condoms, risk reduction counselling, PrEP with emphasis on adherence, follow-up ANC visits). A woman who chooses to initiate PrEP receives clinical and laboratory assessments, adherence counselling and repeat HIV testing.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-255866/blocks/figure-vfig-p010",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../figures/vfig-p010.webp",
      "narrative": "draft",
      "content": "Page render including Figure 3, 'Kenyan risk assessment scoring tool' (source: Pintye et al, 2016): a table of risk factors with value per factor and blank columns for complete and simplified scores – number of lifetime sexual partners (1 point per partner, enter at least 1); male partner HIV status (known or no partner 0, unknown 6); syphilis (RPR nonreactive 0, reactive 5); bacterial vaginosis (negative or not screened 0, positive 2); candidiasis (negative or not screened 0, positive 3); and a total risk score row. Surrounding text and two callout boxes on HIV risk assessment tools and PrEP for women trying to conceive are partly cut off at the left.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PrEP for safer conception",
      "pageStart": 10,
      "pageEnd": 11,
      "target": "../sections/sec-007-prep-for-safer-conception.md",
      "narrative": null,
      "content": "HIV-negative women in high prevalence settings remain at high HIV risk during \nthe period of conception when their partners are of unknown status, or their \npartners are living with HIV and are either (a) not on ART or (b) are not virally \nsuppressed (including partners recently starting ART, whose full viral \nsuppression may take up to six months). Offering PrEP during this time could \ndecrease the risk of viral transmission to the HIV-negative woman and reduce \nanxiety about HIV transmission at a time when couples are not always using \ncondoms to prevent HIV transmission. The decision whethe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses offering PrEP for safer conception to HIV-negative women whose partners have unknown status or are not virally suppressed, stressing that the decision rests with the woman. A Kenyan risk assessment scoring tool for pregnant women is shown as an example.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring PrEP use by pregnant and breastfeeding women",
      "pageStart": 11,
      "pageEnd": 12,
      "target": "../sections/sec-008-monitoring-prep-use-by-pregnant-and-breastfeedin.md",
      "narrative": null,
      "content": "Although the currently available data are reassuring regarding the safety of PrEP during pregnancy and breastfeeding, \nactive surveillance of mother and infant outcomes during PrEP use in pregnancy and breastfeeding should be part of a \nPrEP programme. WHO currently recommends1 that the active surveillance of ARV drug toxicity during pregnancy and the \nbreastfeeding period focus on three areas. These three areas should also be monitored during PrEP use. \n1.\t Maternal adverse outcomes: monitoring treatment-limiting toxicities associated with ART in pregnant women, \nparticularly mortality; \n2.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out how mother and infant outcomes should be actively monitored when PrEP is used in pregnancy and breastfeeding, covering maternal toxicity, adverse birth outcomes and infant growth and development. It also suggests integrating PrEP indicators into existing drug toxicity surveillance and continuity of PrEP services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of issues and considerations",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-009-summary-of-issues-and-considerations.md",
      "narrative": null,
      "content": "Issues\nConsiderations\nPregnancy and \nbreastfeeding \nPrEP can be started or continued during pregnancy and breastfeeding in women at substantial risk of HIV acquisition.\nA range of interventions should be offered to HIV-negative women in pregnancy and breastfeeding to prevent and detect \nincident HIV. These include condom promotion, counselling to reduce risk, risk assessment, STI screening and treatment, \npartner testing and treatment, repeat HIV testing and PrEP for women at substantial risk of HIV infection.\nDesire to conceive\nConsider PrEP for HIV-negative women in serodiscordant relationsh",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A summary table of issues and considerations for PrEP use, covering pregnancy and breastfeeding, desire to conceive, family planning, gender-based violence, sex workers and adolescent girls.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key messages",
      "pageStart": 12,
      "pageEnd": 13,
      "target": "../sections/sec-010-key-messages.md",
      "narrative": null,
      "content": "•\t PrEP is safe during pregnancy and breastfeeding. The ARVs used for PrEP, TDF and TDF/FTC, are frequently used in \ncombination with other ARVs for HIV treatment. The latest WHO systematic review suggests that there does not appear \nto be a safety-related rationale for disallowing or discontinuing PrEP during pregnancy and breastfeeding for HIV-\nnegative women who are at continuing risk of HIV acquisition.\n•\t PrEP could be provided as part of a comprehensive package. PrEP is part of a package of combination HIV \nprevention and other services that includes HIV testing services, assisted partne",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists key messages of the brief, including that PrEP is safe in pregnancy and breastfeeding, should be part of a comprehensive prevention package, and depends on adherence. It also covers disclosure, changing periods of risk, compatibility with hormonal contraception and cost-effectiveness.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-255866/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 13,
      "pageEnd": 16,
      "target": "../sections/sec-011-references.md",
      "narrative": null,
      "content": "1.\t\nGuideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015, Geneva: World Health Organization \n(http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/)\n2. \t Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV pre-exposure \nprophylaxis for all populations. AIDS. 2016 Jul 31; 30(12):1973–83.\n3. \t Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public \nhealth approach. Second edition. Geneva: World Health Organiz",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the technical brief on PrEP in pregnancy and breastfeeding, citing WHO HIV guidelines and studies on TDF safety and HIV risk in pregnant women, followed by WHO HIV department contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
